If death is one of the only certainties in life, then surely it is logical to want to delay it for as long as possible? The quest for eternal life has been a perennial one, recorded in myths since antiquity. Science has thrown billions of Dollars at the challenge. We first wrote on the topic in 2016. “The Economist” featured the subject on its cover recently. However, perhaps the most worthwhile thing many readers can do is obtain a copy of “Outlive.”

Published in March this year and written by Dr Peter Attia, a Canadian physician, “Outlive” (which was recently gifted to your author by a generous colleague) provides a framework for how to live longer. At the heart of the work is the concept of what Dr Attia calls ‘Medicine 3.0.’ In contrast to current approaches to healthcare, under Attia’s framework, the most significant emphasis is placed on prevention rather than treatment. There is also a clear recognition of each person as an individual and a robust assessment of risk. Such a world view is consistent with the thesis we have had since 2012 about the personalisation of healthcare and a shift in the paradigm from reactive to pre-emptive healthcare.

Part of the appeal of “Outlive” is that much of its advice can be seen as common sense. Attia makes the case for how individuals should include exercise regimes (particularly focusing on improving stability) and better eating habits into their lifestyles. The latter point has been addressed significantly in our own work since at least 2014. Attia also highlights the importance of sleep and devotes the final chapter of the work to why mental health matters as much as physical.

It is hard to disagree with Attia’s assertions, albeit that they appear to be written from the perspective of someone who can afford to make better lifestyle choices. Not everyone has such (financial) ability. Governments, in our view, should play a more proactive role in education and the taxation of certain food stuffs could also be helpful. Optimists will also hope that scientific progress will advance. The well-documented success of anti-obesity drugs such as Wegovy suggest one way forward. Ultimately, evolution may be our biggest headwind. All human bodies contain trillions of cells in need of constant rejuvenation.

10 October 2023

The above does not constitute investment advice and is the sole opinion of the author at the time of publication. Past performance is no guide to future performance and the value of investments and income from them can fall as well as rise.

Click here to view all Blog posts.

Alex Gunz, Fund Manager

Disclaimers

The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital LLP believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital LLP, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital LLP is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital LLP disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document. 

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital LLP’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital LLP’s prior written consent. 

Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
email [email protected] 

Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority 

Heptagon Capital Limited is licenced to conduct investment services by the Malta Financial Services Authority.

Related Insights

Season 6, Post 9: At the AIrport
  • Featured Insights

Season 6, Post 9: At the AIrport

Season 6, Post 8: The transition mission
  • Featured Insights

Season 6, Post 8: The transition mission

Future Housing: Home! Sustainable Home!
  • Featured Insights

Future Housing: Home! Sustainable Home!

GET THE UPDATES

Sign up to our monthly email newsletter for the latest fund updates, webcasts and insights.